(Q37849391)

24 August 2017

1 reference

title

Clinical management of Staphylococcus aureus bacteraemia (English)

1 reference

24 August 2017

Staphylococcus aureus

1 reference

Effrossyni Gkrania-Klotsas

inferred from title

author

3

Effrossyni Gkrania-Klotsas

0 references

Martin J Llewelyn

Martin J Llewelyn

10

0 references

Guy E. Thwaites

Guy E Thwaites

1

0 references

Andrew Kirby

Andrew Kirby

4

0 references

Ann Sarah Walker

7

Sarah Walker

1 reference

24 August 2017

6

M Estée Török

1 reference

24 August 2017

Jonathan D Edgeworth

2

1 reference

24 August 2017

Robert Tilley

5

1 reference

24 August 2017

Heiman Fl Wertheim

8

1 reference

24 August 2017

Peter Wilson

9

1 reference

24 August 2017

UK Clinical Infection Research Group

11

1 reference

24 August 2017

1 March 2011

1 reference

Lancet Infectious Diseases

24 August 2017

1 reference

24 August 2017

11

1 reference

24 August 2017

3

1 reference

24 August 2017

208-222

1 reference

Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database

24 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the Eu

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Clinical identifiers of complicated Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Risk factors for metastatic infection in patients with Staphylococcus aureus bacteremia with and without endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Fifteen years' experience with staphylococcus septicemia in a large city hospital; analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Endocarditis caused by Staphylococcus aureus: A reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Staphylococcus aureus infective endocarditis: diagnosis and management guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

The fate of acute methicillin-resistant Staphylococcus aureus periprosthetic knee infections treated by open debridement and retention of components

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Management of bone and joint infections due to Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

The role of transthoracic echocardiography in excluding left sided infective endocarditis in Staphylococcus aureus bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Management of catheter-related Staphylococcus aureus bacteremia: when may sonographic study be unnecessary?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Echocardiography in infective endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Diagnostic value of transesophageal compared with transthoracic echocardiography in infective endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Transesophageal echocardiography in diagnosis of infective endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Mechanical prosthetic valve-associated strands: Pathologic correlates to transesophageal echocardiography.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Evaluation of clinical guidelines for the management of Staphylococcus aureus bacteraemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Right-sided endocarditis caused by Staphylococcus aureus in drug abusers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

The efficacy of the combination of teicoplanin or flucloxacillin with netilmicin in the treatment of Staphylococcus aureus bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Risk factors for recurrence in patients with Staphylococcus aureus infections complicated by bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Risk factors for recurrence after Staphylococcus aureus bacteraemia. A retrospective matched case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an Emergency Department of a medical centre in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Ceftazidime in severe infections: a Swiss multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Cefazolin therapy for Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Staphylococcus aureus septicaemia treated with cefotaxime.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Experience with cefotaxime in infections caused by gram-positive pathogens, especially Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Efficacy of a twelve-hourly ceftriaxone regimen in the treatment of serious bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Ceftriaxone monotherapy for severe bacteremic infections. Spanish Ceftriaxone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

A critical review of the dosage of teicoplanin in Europe and the USA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

The use and therapeutic drug monitoring of teicoplanin in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Staphylococcus aureus bacteremia caused by infected intravenous catheters

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Development of bacteraemia or fungaemia after removal of colonized central venous catheters in patients with negative concomitant blood cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Relationship of staphylococcal tolerance, teichoic acid antibody, and serum bactericidal activity to therapeutic outcome in Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Therapy of Staphylococcus aureus Bacteremia Associated with a Removable Focus of Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Long-term infectious complications and their relation to treatment duration in catheter-related Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Pacemaker infection due to Mycobacterium fortuitum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Cannula-associated Staphylococcus aureus bacteraemia: outcome in relation to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Grupo de Estudio de Enfermedades Infecciosas de la Provincia de Cádiz

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Bacteremia due to Staphylococcus aureus in patients with cancer: report on 45 cases in adults and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Single or Combination Therapy of Staphylococcal Endocarditis in Intravenous Drug Abusers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Staphylococcus aureus bacteraemia: 400 episodes in St Thomas's Hospital.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Fusidic acid in septicaemia and endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

United States resistance surveillance results for linezolid (LEADER Program for 2007).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Heteroresistance: a concern of increasing clinical significance?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Clinical outcomes with daptomycin: a post-marketing, real-world evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Infections caused by Gram-positive bacteria: a review of the global challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Initial low-dose aminoglycosides in Staphylococcus aureus bacteremia: good science, urban legend, or just plain toxic?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

An outbreak in an intensive care unit of a strain of methicillin-resistant Staphylococcus aureus sequence type 239 associated with an increased rate of vascular access device-related bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970285-1

7 January 2021

10.1016/S1473-3099(10)70285-1

Identifiers

DOI

1 reference

24 August 2017

1 reference